Jun Li

Jun Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
SYShousong Yue
Shousong Yue
ZZZhenzhong Zhang
Zhenzhong Zhang
FBFei Bian
Fei Bian
ZYZhang Yan
Zhang Yan
GCGao Chen
Gao Chen
Jean-François PicimbonJean-François Picimbon
Jean-François Picimbon
We demonstrated the role of natural probiotics 3L, 3 Lactobacilli, in the establishment of a strong and sustainable beneficial healthy gut flora, after chemotherapy through experimental results through in vivo model. Using rat CTX model (immunosuppression induced by cyclophosphamide), we suggested some new adjuvant to chemotherapy as drugs + lactobacillus treament. Further, we proposed a new probiotic formulation (L. acidophilus + L. casei + L. plantarum) to be explored in the prevention of health condition loss by alteration of the general immune system, in numerous studies that reported the use of probiotics involving Lactobacillus in the post-chemo or post-surgical procedures. Here, in our study, Illumina MiSeq sequencing was used to generate sequencing data from microbial genomic DNA libraries, which is appreciable to check for the effects of 3L on bacteria. Microbiome analysis, phylogenetic and classification reports, community data have supported the experiments and the results where 3L had strong beneficial effects on the microbiome. Further, the influence on specific metabolic pathways are assisted in deriving the conclusion of the study (use of 3L for cancer therapy) to the mode of action, mechanistically by correcting microbiota composition and enhancing specific gut metabolic functions.

6 July 2023 in Microbiology Research
Verified
Journal Article
Open access
PDF file
SYShousong Yue
Shousong Yue
ZZZhenzhong Zhang
Zhenzhong Zhang
FBFei Bian
Fei Bian
ZYZhang Yan
Zhang Yan
GCGao Chen
Gao Chen
Jean-François PicimbonJean-François Picimbon
Jean-François Picimbon
We deal with various strains of Lactobacillus that can maintain the intestinal microbiome of rats treated with cyclophosphamide, an anticancer agent (chemotherapy). We use MiSeq and various types of statistical tests to prove that cyclophosphamide in rats alters the intestinal microbiome, favoring the growth of various fungi that are extremely harmful to intestinal metabolism. On the contrary, when Lactobacillus 3L is administered together with cyclophosphamide, we prove that the microbiome is preserved by having a much better intestinal metabolism.